ClinicalTrials.gg
RecruitingNCT05942703PAROBIOTAUpdated Jul 12, 2023

Relationship Between Porphyromonas Gingivalis and Obesity in Patients With Periodontitis

An observational study in Obesity, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
311
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Obesity by University Hospital, Toulouse — 6 open to participants now, 6 under way, none of them phase 3. Obesity · University Hospital, Toulouse.

Started
2022
with 1 other
Observational
3 of 18
2 open now
Registered
15th of 18
by date

Among the 18 studies in Obesity by University Hospital, Toulouse, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 15th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 18 studies in Obesity by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Obesity by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Obesity is recognized as a major public health problem. Recent research suggests the involvement of the gut microbiota in the development of obesity. Indeed, obese people are characterized by a dysbiotic intestinal microbiota. Periodontitis are chronic inflammatory oral pathologies linked to an imbalance between the bacterial etiological factor, oral dysbiosis, and the host's immune defenses.They lead to the destruction of the supporting tissues of the tooth and an apical migration of the periodontal attachment system, thus leading to the formation of the pathognomonic entity of the disease, the periodontal pocket.the presence of bacteria of oral origin such as Porphyromonas gingivalis (Pg) has been demonstrated in the adipose tissue of obese patients inducing a chronic low-grade inflammatory response by macrophages which leads to the proliferation of adipocyte precursors predisposing to obesity. The main objective is to assess the average amount of Porphyromonas gingivalis (Pg) in the saliva of obese people (BMI ≥ 30) with periodontitis.

Read the detailed description

Obesity is recognized as a major public health problem. Recent research suggests the involvement of the gut microbiota in the development of obesity. Indeed, obese people are characterized by a dysbiotic intestinal microbiota. Periodontitis are chronic inflammatory oral pathologies linked to an imbalance between the bacterial etiological factor, oral dysbiosis, and the host's immune defenses.They lead to the destruction of the supporting tissues of the tooth and an apical migration of the periodontal attachment system, thus leading to the formation of the pathognomonic entity of the disease, the periodontal pocket.the presence of bacteria of oral origin such as Porphyromonas gingivalis (Pg) has been demonstrated in the adipose tissue of obese patients inducing a chronic low-grade inflammatory response by macrophages which leads to the proliferation of adipocyte precursors predisposing to obesity. The main objective is to assess the average amount of Porphyromonas gingivalis (Pg) in the saliva of obese people (BMI ≥ 30) with periodontitis.This study is a comparative cross-sectional non-interventional study with retrospective and prospective and consecutive recruitment of participants.

Prospective patient recruitment:

During the patient's visit to the periodontology department, if the patient has periodontitis and has given his non-objection, he will be included in the study. A routine check-up in odontology will then be carried out: complete medical questionnaire (general, hygiene and dietetics), clinical examination (visual examination and statement of periodontal indices), radiological examination. Samples of saliva and periodontal plaque, conventionally taken in current dental surgery practice in the periodontal management of patients, will be used to carry out bacterial assays. CThe saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

any patient coming for consultation in the periodontology department

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 18 years old
  • having periodontitis
  • able to receive information on the course of the study and to understand the information form to participate in the study.
  • having given their non-objection to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Having taken antibiotics, prebiotics or probiotics in the month prior to inclusion
  • During pregnancy or breastfeeding
  • With a history of oral surgery in the month prior to inclusion
  • At risk of infection (existence of one or more known chronic infectious diseases)
  • Suffering from a general pathology contraindicating the performance of diagnostic procedures such as periodontal probing (patients at high risk of infective endocarditis according to the French National Agency for the Safety of Medicines and Products of Health ANSM)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
311 participants (estimated)
Patient registry
No

Groups and cohorts

  • obese patients

    Patients with a body mass index superior or equal at 30 and with a periodontitis

    Other: saliva samples

  • non-obese (BMI<30) patients

    Patients with a body mass index inferior at 30 with a periodontitis

    Other: saliva samples

Interventions

  • Othersaliva samples

    Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment

    Also known as: periodontal plaque samples

06

What researchers measure

Primary outcomes

  1. Analysis by bacterial culture and taxonomic analysis (MiSEQ) of the microbiological composition of saliva

    Assess the microbiological composition of saliva and periodontal plaque in obese (BMI≥30) and non-obese (BMI\<30) patients with periodontitis.

    Time frame: 8 weeks

  2. Analysis by bacterial culture and taxonomic analysis (MiSEQ) of the microbiological composition periodontal plaque

    Assess the microbiological composition of periodontal plaque in obese (BMI≥30) and non-obese (BMI\<30) patients with periodontitis.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2024, 15 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 15 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Jul 12, 2023
StartActual
Dec 5, 2022
Primary completionEst.
Mar 27, 2024
CompletionEst.
Dec 30, 2024
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942703
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Dec 5, 2022
Primary completion
Mar 27, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jul 12, 2023

Study contacts

Sara LAURENCIN, MD
Contact
laurencin.s@chu-toulouse.fr
0561344473 ext. +33
Cathy NABET, Pr
Contact
catherine.nabet@univ-tlse3.fr
Sara LAURENCIN, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion